Sage Therapeutics, Inc.

The conference will begin shortly. To raise your hand during Q&A, you can dial star 1 1. Good morning.

Welcome to Sage Therapeutics' second quarter 2022 financial results conference call. Currently, all participants are in listen-only mode. This call is being webcast live on the Investors in Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics, and recording, reproduction, or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded. I'd now like to introduce Helen Rubenstein, Director of Investor Relations at Sage.

Good morning, and thank you for joining Sage Therapeutics' second quarter 2022 financial results conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com, where you can find the press release related to today's call, as well as the slides that contain supplemental details. I'd like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please consult our risk factors discussed in today's press release and in our SEC filings for additional details. We will begin the call with prepared remarks by Barry Green, our Chief Executive Officer, who will provide an overview of our progress during the second quarter. We will also be joined by Al Robichaux, our Chief Scientific Officer, who will review recent progress in development activities across our program. Chris Bonecki, our Chief Business Officer, will provide an update on our progress preparing for the launch of the rental loan in MDD and PPD, if approved. And Kimi Iguchi, our Chief Financial Officer, will review the financial results from the quarter. With that, I'll now turn the call over to Barry.